Shenzhen Shenxin Biotechnology Co., Ltd
Clinical trials sponsored by Shenzhen Shenxin Biotechnology Co., Ltd, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New mRNA vaccine takes aim at RSV in early human trial Results expected Apr 2027 (estimated)
-
New mRNA vaccine takes aim at RSV in early human trial
Vaccine OngoingThis early-stage trial is testing a new mRNA vaccine called IN006 that targets respiratory syncytial virus (RSV). About 240 healthy adults aged 18 and older will receive either the vaccine or a placebo. The main goal is to check if the vaccine is safe and triggers an immune respo…
Phase 1 • Sponsor: Shenzhen Shenxin Biotechnology Co., Ltd • Aim: Vaccine
Last updated Jun 27, 2026 12:03 UTC
-
New mRNA vaccine aims to shield seniors from RSV
Vaccine OngoingThis study tests a new mRNA vaccine called IN006 against respiratory syncytial virus (RSV) in 500 healthy adults aged 60 and older. The vaccine is given as two different doses, with a booster after 12 or 24 months. Researchers will monitor safety and measure immune responses like…
Phase 2 • Sponsor: Shenzhen Shenxin Biotechnology Co., Ltd • Aim: Vaccine
Last updated Jun 26, 2026 14:29 UTC